You have read all your free articles, to continue reading subscribe to read the rest of this content.
InDex Pharmaceuticals has announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The analysis confirms that theAlready a subscriber Login You have read all your…
Athera Biotechnologies announces that first dosing in a multiple dosing study in healthy volunteers has been done with its fully human antibody PC-mAb, less than three weeks after regulatory authority approval. “We are pleased to have executed our plans in such a timely manner and are looking fAlready a subscriber…
The US Food and Drug Administration, FDA, has issued a safety alert to patients and health care professionals, regarding an increased risk of death associated with Pepaxto (melphalan flufenamide), in the OCEAN study. The company has an ongoing dialogue with the FDA and will provide updated informAlready a subscriber Login…
Benralizumab, AZ's potential new medicine and anti-eosinophil monoclonal antibody, has been well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials. This demonstrates significant reductions in the annual asthma exacerbation rate compared to placebo. Already a subscriber Login You have read all your free articles, to continue…
